Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Share-based Compensation (2022 - 2025)

Coya Therapeutics' Share-based Compensation history spans 4 years, with the latest figure at $1.1 million for Q3 2025.

  • For Q3 2025, Share-based Compensation rose 38.18% year-over-year to $1.1 million; the TTM value through Sep 2025 reached $4.0 million, up 88.41%, while the annual FY2024 figure was $2.7 million, 205.36% up from the prior year.
  • Share-based Compensation for Q3 2025 was $1.1 million at Coya Therapeutics, up from $1.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.1 million in Q1 2025 and bottomed at $21425.0 in Q1 2022.
  • The 4-year median for Share-based Compensation is $262752.0 (2023), against an average of $461988.0.
  • The largest annual shift saw Share-based Compensation skyrocketed 741.95% in 2023 before it soared 38.18% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $71429.0 in 2022, then surged by 233.2% to $237999.0 in 2023, then soared by 232.16% to $790549.0 in 2024, then soared by 35.46% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Share-based Compensation are $1.1 million (Q3 2025), $1.0 million (Q2 2025), and $1.1 million (Q1 2025).